Age, menopause, bone turnover markers and lumbar bone loss in healthy Japanese women

被引:39
作者
Iki, M
Kajita, E
Dohi, Y
Nishino, H
Kusaka, Y
Tsuchida, C
Yamamoto, K
Ishii, Y
机构
[1] TOYAMA MED & PHARMACEUT UNIV, FAC MED, DEPT COMMUNITY & GERIAT NURSING, TOYAMA 93001, JAPAN
[2] NARA MED UNIV, DEPT PUBL HLTH, KASHIHARA, NARA 634, JAPAN
[3] TOYAMA INST HLTH, DEPT ENVIRONM HLTH, KOSUGI, TOYAMA 93903, JAPAN
[4] FUKUI MED SCH, DEPT RADIOL, MATSUOKA, FUKUI 91011, JAPAN
关键词
lumbar spine bone density; bone turnover markers; Japanese women; longitudinal study; osteoporosis;
D O I
10.1016/0378-5122(96)01042-0
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The change in lumbar vertebral bone mineral density (BMD) during a 2-year study period was examined in 167 healthy middle-aged and elderly Japanese women with reference to age, menopausal status and bone turnover markers at baseline. The perimenopausal and postmenopausal groups of the subjects showed a significant loss of BMD during the study period but the premenopausal women did not. The annual percent decrease of BMD (Delta BMD) in the perimenopausal women (- 2.40% in average) was significantly greater than that in either of the premenopausal (- 0.01%) or over-all postmenopausal women (- 0.85%). The subjects who had been postmenopausal for less than 10 years showed a significant bone loss. Delta BMD in the postmenopausal women became less marked as the postmenopausal duration increased. The bone loss was accelerated for about 10 years after menopause. The pattern and magnitude of bone loss of Japanese women seemed to be similar to those of Caucasian women. The regression equation for Delta BMD based on the bone turnover markers at baseline was shown to be significant in the postmenopausal women and the serum level of bone-specific alkaline phosphatase isoenzyme had a significant relation to Delta BMD. However, this equation accounted for only 17.3% of the total variance of Delta BMD and, hence, its validity was not sufficiently high for the prediction of bone loss in clinical settings.
引用
收藏
页码:59 / 67
页数:9
相关论文
共 47 条
[1]  
Bergman I, 1970, Clin Chim Acta, V27, P347, DOI 10.1016/0009-8981(70)90355-4
[2]   APPLICATIONS OF AN ENZYME-IMMUNOASSAY FOR A NEW MARKER OF BONE-RESORPTION (CROSSLAPS) - FOLLOW-UP ON HORMONE REPLACEMENT THERAPY AND OSTEOPOROSIS RISK ASSESSMENT [J].
BONDE, M ;
QVIST, P ;
FLEDELIUS, C ;
RIIS, BJ ;
CHRISTIANSEN, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :864-868
[3]  
BONDE M, 1994, CLIN CHEM, V40, P2022
[4]  
Christiansen C, 1990, Osteoporos Int, V1, P35, DOI 10.1007/BF01880414
[5]  
CHRISTIANSEN C, 1987, LANCET, V1, P1106
[6]  
CONNERTY HV, 1966, AM J CLIN PATHOL, V45, P290
[7]  
DEPALMA L, 1992, ACTA ORTHOP SCAND, V63, P645
[8]   RATE OF SPINAL TRABECULAR BONE LOSS IN NORMAL PERIMENOPAUSAL WOMEN - CT MEASUREMENT [J].
FIROOZNIA, H ;
GOLIMBU, C ;
RAFII, M ;
SCHWARTZ, MS .
RADIOLOGY, 1986, 161 (03) :735-738
[9]   COMPARISON OF NEW BIOCHEMICAL MARKERS OF BONE TURNOVER IN LATE POSTMENOPAUSAL OSTEOPOROTIC WOMEN IN RESPONSE TO ALENDRONATE TREATMENT [J].
GARNERO, P ;
SHIH, WCJ ;
GINEYTS, E ;
KARPF, DB ;
DELMAS, PD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (06) :1693-1700
[10]  
HAGINO H, 1992, J BONE MINER RES, V7, P147